Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Inclusion criteria: * Screening Visit * Age: 20-80 * High risk for cardiovascular disease according to NCEP APT III * TG≥300mg/dL and 160mg/dL\>LDL-C≥100mg/dL for subjects who were not taking statins for 4 weeks * 500mg/dL\>TG≥200mg/dL and LDL-C\<110mg/dL for subjects who were taking statins for 4 weeks * Baseline Visit * 500mg/dL\>TG≥200mg/dL * LDL-C\<110mg/dL * Reduction of LDL-C comparing screening visit Exclusion criteria: * The patient has histories of acute artery disease within 3 months * The patient has histories of operation revasculariation or aneurysm within 6 months * The patient has histories of unexplained myalgia or diagnosed myalgia or rhabdomyolysis * The patient has histories of effect able disease to the procedure and clinical trial result